readthroughSign in
Nov 12, 2026Financing

Addex spin-out Neurosterix raises $105 million in Series B round

Addex's stake in Neurosterix now stands at 8.5%, with the new funds aimed mainly at advancing NTX-253 into Phase 2 testing for schizophrenia.

Addex Therapeutics announced on November 11, 2026 that its spin-out company, Neurosterix, completed a $105 million Series B financing round backed by a group of life science investors. Addex did not take part in the round, and its stake in Neurosterix is now valued at 8.5% of issued capital, corresponding to an $18.6 million valuation.1

According to the release, most of the new capital will go toward moving NTX-253, a muscarinic M4 positive allosteric modulator, into planned Phase 2 trials for schizophrenia.1 The remaining funds will support Neurosterix's wider pipeline of allosteric modulators targeting other neuropsychiatric conditions.1

On the science, the company described NTX-253 as an oral compound designed to adjust muscarinic signaling in a way that could ease psychosis symptoms without producing the movement-related and metabolic side effects tied to standard dopamine-blocking antipsychotics. Neurosterix has finished Phase 1 single- and multiple-ascending-dose studies of NTX-253, and the resulting data support moving to larger Phase 2 trials.1

Neurosterix's broader pipeline includes NTX-253 for schizophrenia, an mGlu7 negative allosteric modulator called NTX-819 aimed at mood and anxiety disorders, and a second M4-targeted compound, NTX-529, intended for additional psychosis and mood-related conditions. The company runs operations out of Boston and Geneva.

Separately, the filing noted that Addex's own pipeline includes dipraglurant, an mGlu5 negative allosteric modulator under evaluation for brain injury recovery including post-stroke and traumatic brain injury, a GABAB PAM candidate that has completed IND-enabling studies for substance use disorders, and a separate GABAB PAM compound being developed for chronic cough.1 Addex has also made an investment in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.